Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 6 de 6
Filter
Add more filters










Database
Type of study
Language
Publication year range
1.
Purinergic Signal ; 17(2): 229-240, 2021 06.
Article in English | MEDLINE | ID: mdl-33751327

ABSTRACT

Adenosine triphosphate (ATP) and its metabolites adenosine diphosphate, adenosine monophosphate, and adenosine in purinergic signaling pathway play important roles in many diseases. Activation of P2 receptors (P2R) channels and subsequent membrane depolarization can induce accumulation of extracellular ATP, and furtherly cause kinds of diseases, such as pain- and immune-related diseases, cardiac dysfunction, and tumorigenesis. Active ingredients of traditional Chinese herbals which exhibit superior pharmacological activities on diversified P2R channels have been considered as an alternative strategy of disease treatment. Experimental evidence of potential ingredients in Chinese herbs targeting P2R and their pharmacological activities were outlined in the study.


Subject(s)
Drugs, Chinese Herbal/chemistry , Drugs, Chinese Herbal/therapeutic use , Receptors, Purinergic P2/drug effects , Signal Transduction/drug effects , Adenosine Triphosphate/metabolism , Animals , Humans , Purinergic P2 Receptor Agonists/therapeutic use , Purinergic P2 Receptor Antagonists/therapeutic use
2.
Int J Mol Sci ; 22(2)2021 Jan 16.
Article in English | MEDLINE | ID: mdl-33467058

ABSTRACT

Vascular dysfunction in cardiovascular diseases includes vasomotor response impairments, endothelial cells (ECs) activation, and smooth muscle cells (SMCs) proliferation and migration to the intima. This results in intimal hyperplasia and vessel failure. We previously reported that activation of the P2Y11 receptor (P2Y11R) in human dendritic cells, cardiofibroblasts and cardiomyocytes was protective against hypoxia/reoxygenation (HR) lesions. In this study, we investigated the role of P2Y11R signaling in vascular dysfunction. P2Y11R activity was modulated using its pharmacological agonist NF546 and antagonist NF340. Rat aortic rings were exposed to angiotensin II (AngII) and evaluated for their vasomotor response. The P2Y11R agonist NF546 reduced AngII-induced vascular dysfunction by promoting EC-dependent vasorelaxation, through an increased nitric oxide (NO) bioavailability and reduced AngII-induced H2O2 release; these effects were prevented by the use of the P2Y11R antagonist NF340. Human vascular SMCs and ECs were subjected to AngII or H/R simulation in vitro. P2Y11R agonist modulated vasoactive factors in human ECs, that is, endothelial nitric oxide synthase (eNOS) and endothelin-1, reduced SMC proliferation and prevented the switch towards a synthetic phenotype. H/R and AngII increased ECs secretome-induced SMC proliferation, an effect prevented by P2Y11R activation. Thus, our data suggest that P2Y11R activation may protect blood vessels from HR-/AngII-induced injury and reduce vascular dysfunctions. These results open the way for new vasculoprotective interventions.


Subject(s)
Diphosphonates/pharmacology , Naphthalenesulfonates/pharmacology , Purinergic P2 Receptor Agonists/pharmacology , Receptors, Purinergic P2/metabolism , Reperfusion Injury/metabolism , Tunica Intima/pathology , Angiotensin II/toxicity , Animals , Aorta/drug effects , Aorta/metabolism , Aorta/pathology , Aorta/physiopathology , Diphosphonates/therapeutic use , Endothelin-1/metabolism , Human Umbilical Vein Endothelial Cells/drug effects , Human Umbilical Vein Endothelial Cells/metabolism , Humans , Hyperplasia/prevention & control , Male , Myocytes, Smooth Muscle/drug effects , Myocytes, Smooth Muscle/metabolism , Naphthalenesulfonates/therapeutic use , Nitric Oxide/metabolism , Nitric Oxide Synthase Type III/metabolism , Purinergic P2 Receptor Agonists/therapeutic use , Rats , Rats, Wistar , Reperfusion Injury/drug therapy , Tunica Intima/drug effects , Tunica Intima/metabolism , Vasodilation , Water/metabolism
3.
Invest Ophthalmol Vis Sci ; 60(1): 255-264, 2019 01 02.
Article in English | MEDLINE | ID: mdl-30649152

ABSTRACT

Purpose: Exposure to airborne particulate matter can induce ocular surface damage and inflammation. We evaluated the effects of a topical mucin secretagogue on the mitigation of ocular surface damage induced by exposure to airborne carbon black (CB). Methods: Sprague-Dawley rats were exposed to ambient CB for 2 hours twice daily for 5 days. Corneal staining score and tear lactic dehydrogenase (LDH) activity were measured to evaluate ocular surface damage. Serum immunoglobulin (Ig) G and IgE levels and the sizes of cervical lymph nodes were also measured. The expressions of interleukin (IL)-4, IL-17, and interferon (IFN)-γ were measured by Western blot analysis. Diquafosol tetrasodium was instilled six times a day for 5 days, and the extent of ocular surface damage was evaluated. Results: After exposure to airborne CB, the median corneal staining score and LDH activity were significantly increased. Serum IgG and IgE levels and the sizes of cervical lymph nodes were also significantly increased. Additionally, the expression of IL-4 and IFN-γ was elevated in the anterior segment of the eyeball. Furthermore, the expression of IL-4, IL-17, and IFN-γ was elevated in the cervical lymph nodes. When exposed to airborne black carbon, topical diquafosol tetrasodium significantly increased tear MUC5AC concentration and decreased tear LDH activity. Conclusions: Exposure to airborne CB induced ocular surface damage and increased proinflammatory cytokines in the eyes and cervical lymph nodes. Topical mucin secretagogues seem to have a protective effect on the ocular surface against exposure to airborne particulate matters.


Subject(s)
Corneal Diseases/prevention & control , Foreign-Body Reaction/prevention & control , Mucin 5AC/metabolism , Particulate Matter/adverse effects , Polyphosphates/therapeutic use , Purinergic P2 Receptor Agonists/therapeutic use , Secretagogues/metabolism , Uracil Nucleotides/therapeutic use , Animals , Blotting, Western , Corneal Diseases/etiology , Corneal Diseases/metabolism , Cytokines/metabolism , Enzyme-Linked Immunosorbent Assay , Foreign-Body Reaction/etiology , Foreign-Body Reaction/metabolism , Immunoglobulin E/blood , Immunoglobulin G/blood , L-Lactate Dehydrogenase/metabolism , Lymph Nodes/metabolism , Lymph Nodes/pathology , Male , Neck , Rats , Rats, Sprague-Dawley , Soot/adverse effects , Tears/enzymology
4.
Arterioscler Thromb Vasc Biol ; 35(11): 2307-15, 2015 Nov.
Article in English | MEDLINE | ID: mdl-26359511

ABSTRACT

Under various pathological conditions, including thrombosis and inflammation, extracellular nucleotide levels may increase because of both active release and passive leakage from damaged or dying cells. Once in the extracellular compartment, nucleotides interact with plasma membrane receptors belonging to the P2 purinergic family, which are expressed by virtually all circulating blood cells and in most blood vessels. In this review, we focus on the specific role of the 3 platelet P2 receptors P2Y1, P2Y12, and P2X1 in hemostasis and arterial thrombosis. Beyond platelets, these 3 receptors, along with the P2Y2, P2Y6, and P2X7 receptors, constitute the main P2 receptors mediating the proinflammatory effects of nucleotides, which play important roles in various functions of circulating blood cells and cells of the vessel wall. Each of these P2 receptor subtypes specifically contributes to chronic or acute vascular inflammation and related diseases, such as atherosclerosis, restenosis, endotoxemia, and sepsis. The potential for therapeutic targeting of these P2 receptor subtypes is also discussed.


Subject(s)
Inflammation/metabolism , Purines/metabolism , Receptors, Purinergic P2/metabolism , Thrombosis/metabolism , Animals , Anti-Inflammatory Agents/therapeutic use , Blood Coagulation , Fibrinolytic Agents/therapeutic use , Humans , Inflammation/blood , Inflammation/drug therapy , Inflammation Mediators/blood , Purinergic P2 Receptor Agonists/therapeutic use , Purinergic P2 Receptor Antagonists/therapeutic use , Receptors, Purinergic P2/drug effects , Receptors, Purinergic P2X7/metabolism , Receptors, Purinergic P2Y2/metabolism , Signal Transduction , Thrombosis/blood , Thrombosis/drug therapy
5.
Int J Mol Sci ; 15(12): 23672-704, 2014 Dec 18.
Article in English | MEDLINE | ID: mdl-25530618

ABSTRACT

Purinergic signalling plays a crucial role in proper functioning of the nervous system. Mechanisms depending on extracellular nucleotides and their P2 receptors also underlie a number of nervous system dysfunctions. This review aims to present the role of purinergic signalling, with particular focus devoted to role of P2 family receptors, in epilepsy, depression, neuropathic pain, nervous system neoplasms, such as glioma and neuroblastoma, neurodegenerative diseases like Parkinson's disease, Alzheimer's disease and multiple sclerosis. The above-mentioned conditions are associated with changes in expression of extracellular ectonucleotidases, P2X and P2Y receptors in neurons and glial cells, as well as releasing considerable amounts of nucleotides from activated or damaged nervous tissue cells into the extracellular space, which contributes to disturbance in purinergic signalling. The numerous studies indicate a potential possibility of using synthetic agonists/antagonists of P2 receptors in treatment of selected nervous system diseases. This is of particular significance, since numerous available agents reveal a low effectiveness and often produce side effects.


Subject(s)
Nervous System Diseases/metabolism , Receptors, Purinergic P2X/metabolism , Receptors, Purinergic P2Y/metabolism , Animals , Humans , Nervous System Diseases/drug therapy , Nervous System Diseases/genetics , Purinergic P2 Receptor Agonists/pharmacology , Purinergic P2 Receptor Agonists/therapeutic use , Purinergic P2 Receptor Antagonists/pharmacology , Purinergic P2 Receptor Antagonists/therapeutic use , Receptors, Purinergic P2X/chemistry , Receptors, Purinergic P2X/genetics , Receptors, Purinergic P2Y/chemistry , Receptors, Purinergic P2Y/genetics
6.
Neuropharmacology ; 61(1-2): 25-34, 2011.
Article in English | MEDLINE | ID: mdl-21338615

ABSTRACT

While the position of adenosine as an endogenous anticonvulsant is well established, it is unclear to what extent its precursor, ATP, contributes to seizure activity via P2 receptors. In this study we have addressed this issue through the use of ATP biosensors and agonists and antagonists of ATP P2 receptors to detect the release and role of ATP, respectively, during electrically-evoked electrographic seizure-like events (eSLEs) in rat hippocampal slices. The broad-spectrum P2 receptor antagonists RB-2 and PPADS (10µM) caused a small ∼30% inhibition of eSLE duration, and a reduction in intensity. This inhibition of eSLEs was partially reproduced with the P2X(1,2/3,3) antagonist NF023 (10µM), but not the P2X(7) antagonist BBG (10µM). However, the P2X receptor agonist α,ß-meATP did not enhance eSLEs, but instead reduced their duration. Furthermore, we could discern no role for P2Y(1) receptors in electrically-evoked eSLEs: both the P2Y(1) antagonist MRS2179 (10µM) and the P2Y(1) receptor agonist 2-methylthioADP (10µM) were without effect on eSLEs. Consistent with a minor role for ATP P2 receptors on eSLEs we could detect no ATP release during eSLEs, although appreciable quantities of adenosine were detected, which had a pronounced inhibitory action on eSLEs via A(1) receptors. We conclude that the role of ATP P2 receptors in modulating electrographic seizure activity is limited, at least in models such as this one requiring electrical stimulation of afferent fibres. We further conclude that the presence and action of adenosine under these conditions may primarily reflect direct release of this purine.


Subject(s)
Biosensing Techniques/methods , Hippocampus/physiopathology , Purinergic P2 Receptor Agonists/pharmacology , Purinergic P2 Receptor Antagonists/pharmacology , Purines/pharmacology , Receptors, Purinergic P2/physiology , Seizures/physiopathology , Animals , Electric Stimulation/adverse effects , Hippocampus/drug effects , Male , Organ Culture Techniques , Purinergic P2 Receptor Agonists/therapeutic use , Purinergic P2 Receptor Antagonists/therapeutic use , Purines/therapeutic use , Rats , Rats, Sprague-Dawley , Seizures/etiology , Seizures/prevention & control
SELECTION OF CITATIONS
SEARCH DETAIL
...